Dr. Henrich Guntermann, MD, MSc,
President, Europe & Immunology Group

The Immunology Group is located in Germany and includes a research and development facility in Leipzig and a manufacturing facility in Wanzleben. The Group is focused on the development of WF10 for the treatment of immune related diseases. WF10 is a solution of OXO-K993 containing stabilized chlorite ions.

The immune system provides an essential defense to micro-organisms, cancer and substances it sees as foreign and potentially harmful. WF10 focuses on supporting the immune system by targeting certain types of cells, including the macrophage, a white blood cell species that is key for the regulation of normal and pathological immune function.

In early December 2011, the Company acquired the 40% minority interest in Nuvo Research AG (AG). AG owns all of the rights, including intellectual property rights to WF10. Nuvo’s full ownership of AG will provide greater flexibility in the development and financing of WF10.

In 2010, the Immunology Group conducted a successful Phase 2 trial for moderate to severe allergic rhinitis. The Immunology Group completed its evaluation of the entire data set, including the secondary endpoints and based on this evaluation, the Company has initiated a new development plan for WF10 to maximize its value to the Company. The plan focuses future development activities on new potentially superior derivative formulations of WF10 for which the Company filed a patent application in December 2011. In 2012 and 2013, the Company plans to conduct preclinical studies to confirm the stability, efficacy and safety of the new WF10 formulations relative to existing WF10 which demonstrated efficacy.